DAPA-CKD documented the effect of 5 or 10 mg/day of dapagliflozin in patients with an eGFR 25–75 ml/min/1.73m2 and urinary albumin excretion of between 200–5000 mg/g [46]. Here, ALB is linked to chronic kidney disease.